United Pharm (033270)

Seoul

Currency in KRW

20,800

0(0.00%)

Delayed Data·12/08

Fair Value

Unlock Value

Day's Range

20,700

21,000

52 wk Range

17,250

23,850

033270 Income Statement

Featured here, the Income Statement (earnings report) for United Pharm, showing the company's financial performance from operating and non operating activities such as revenue, expenses and income for the last 4 periods (either quarterly or annually).

Period Ending:

2006

31/03

2007

31/03

2007

31/12

2008

31/12

2009

31/12

2010

31/12

2011

31/12

2012

31/12

2013

31/12

2014

31/12

Total Revenues

aa.aa

134,978.55

145,453.05

134,829.85

136,891.13

155,189.55

Total Revenues Growth

aa.aa

+13.35%

+7.76%

-7.3%

+1.53%

+13.37%

Cost Of Revenues

aa.aa

52,887.07

59,465.1

62,392.72

67,228.23

74,201.2

Gross Profit

aa.aa

82,091.48

85,987.95

72,437.13

69,662.9

80,988.36

Gross Profit Growth

aa.aa

+7.01%

+4.75%

-15.76%

-3.83%

+16.26%

Gross Profit Margin %

aa.aa

60.82%

59.12%

53.72%

50.89%

52.19%

Other Operating Expenses, Total

aa.aa

62,011.34

58,959.1

52,927.02

54,825.72

58,501.39

	Other Operating Expenses, Total Growth
	R&D Expenses
	Selling General & Admin Expenses
	Other Operating Expenses

aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	+6.01%	-4.92%	-10.23%	+3.59%	+6.7%
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	1,529.79	1,271.63	1,299.04	3,004.79	3,988.62
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	58,260.93	55,468.75	49,574.93	49,633.81	52,577.37
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	709.16	784.89	766.86	919.87	830.55

Operating Income

aa.aa

20,080.14

27,028.85

19,510.11

14,837.18

22,486.97

Operating Income Growth

aa.aa

+10.22%

+34.6%

-27.82%

-23.95%

+51.56%

EBIT Margin %

aa.aa

14.88%

18.58%

14.47%

10.84%

14.49%

Net Interest Expenses

aa.aa

-945.67

-933

37.57

31.19

-376.18

Net Interest Expenses Growth

aa.aa

-51.27%

+1.34%

+104.03%

-16.98%

-1,306.08%

Interest Expense, Total

aa.aa

-1,306.67

-1,437.99

-911.63

-982.57

-1,015.17

Interest And Investment Income

aa.aa

361.01

504.99

949.2

1,013.76

639

Other Non Operating Expenses, Total

aa.aa

-336.87

-3,255.36

1,663.29

781.04

704.36

EBT, Excl. Unusual Items

aa.aa

18,797.6

22,840.48

21,210.98

15,649.41

22,815.16

Gain (Loss) On Sale Of Assets

aa.aa

806.11

-79.32

-648.15

-10.93

-33.23

Other Unusual Items, Total

aa.aa

EBT, Incl. Unusual Items

aa.aa

19,603.71

22,725.34

20,561.83

15,568.95

22,779.55

EBT, Incl. Unusual Items Growth

aa.aa

+28.38%

+15.92%

-9.52%

-24.28%

+46.31%

EBT, Incl. Unusual Items Margin

aa.aa

14.52%

15.62%

15.25%

11.37%

14.68%

Income Tax Expense

aa.aa

2,544.02

2,527.93

4,191.41

3,364.73

4,300.22

Net Income to Company

aa.aa

17,059.7

20,197.41

16,370.42

12,204.22

18,479.33

Minority Interest

aa.aa

-4.06

10.65

8.41

8.17

-104.49

Net Income

aa.aa

17,055.63

20,208.06

16,378.83

12,212.39

18,374.83

Net Income Growth

aa.aa

+20.11%

+18.48%

-18.95%

-25.44%

+50.46%

Net Income Margin %

aa.aa

12.64%

13.89%

12.15%

8.92%

11.84%

Preferred Dividend and Other Adjustments

aa.aa

Net Income to Common Excl. Extra Items

aa.aa

17,055.63

20,208.06

16,378.83

12,212.39

18,374.83

Basic EPS - Continuing Operations

aa.aa

1,148.04

1,398.04

1,081

775

1,163.44

Basic EPS - Continuing Operations Growth

aa.aa

+23.11%

+21.78%

-22.68%

-28.31%

+50.12%

Diluted EPS - Continuing Operations

aa.aa

1,133.33

1,386.27

1,081

766

1,160

Diluted EPS - Continuing Operations Growth

aa.aa

+22.85%

+22.32%

-22.02%

-29.14%

+51.44%

Basic Weighted Average Shares Outstanding

aa.aa

14.86

14.45

15.15

15.76

15.79

Diluted Weighted Average Shares Outstanding

aa.aa

15.05

14.58

15.15

15.94

15.84

Dividend Per Share

aa.aa

Dividend Per Share Growth

aa.aa

EBITDA

aa.aa

24,380.96

31,344.66

23,983.2

21,011.97

29,639.37

EBITDA Growth

aa.aa

+9.75%

+28.56%

-23.49%

-12.39%

+41.06%

EBITDA Margin %

aa.aa

18.06%

21.55%

17.79%

15.35%

19.1%

EBIT

aa.aa

20,080.14

27,028.85

19,510.11

14,837.18

22,486.97

* In Millions of KRW (except for per share items)

NSE 30

5,328.61

-1.12

-0.02%

NSE All Share

146,055.88

+107.40

+0.07%

US 30

44,469.50

+10.8

+0.02%

US 500

6,447.10

+1.3

+0.02%

FTSE 100

9,147.81

+18.10

+0.20%

DAX

24,024.78

-56.56

-0.23%

South Africa Top 40

93,808.58

+525.91

+0.56%

Market Movers

Name	Last	Chg. %	Vol.
Access Holdings	27.55	-0.54%	61.09M
Zenith Bank	74.00	0.00%	27.39M
Nigerian Breweries	74.40	0.00%	27.12M
Guaranty Trust Holding	99.00	-0.85%	26.50M
UBA	48.70	+1.25%	17.85M
Dangote Cement	577.00	0.00%	4.44M
Aradel Holdings	520.00	0.00%	1.89M

Name	Last	Chg. %	Vol.
Prestige	2.20	+10.00%	7.86M
Champion Brew	17.38	+10.00%	6.86M
Mansard Ins	17.710	+10.00%	4.73M
Sunu Assurances	6.05	+10.00%	13.54M
Abctrans	4.95	+10.00%	1.49M
Initiates	14.52	+10.00%	4.88M
Ellah Lakes	16.06	+10.00%	26.26M

Name	Last	Chg. %	Vol.
Juli	9.00	-10.00%	101.69K
Unilever Nigeria	71.30	-9.97%	4.19M
Custodian Allied	37.90	-9.55%	1.87M
Academy Press	8.30	-7.78%	1.07M
Maybaker	18.000	-7.69%	1.69M
Wema Bank	21.75	-6.05%	3.91M
Livestock	8.45	-5.06%	4.09M

Trending Stocks

Name	Last	Chg. %	Vol.
Aiico	4.23	+9.87%	64.99M
Linkassure	2.48	+9.73%	11.77M
Ellah Lakes	16.06	+10.00%	26.26M
Mutual Benefits Assurance	3.53	+9.97%	30.37M
Access Holdings	27.55	-0.54%	61.09M

Most Undervalued Stocks

Name	Last	Upside	Fair Value
Aaaaaaaaaaaaaa	577.00	+40.93%	813.17
A Aaa A Aa Aaaa Aaaa	1,890.00	+34.32%	2,538.65
Aaaaaaaaa	71.00	+26.96%	90.14
Aaa Aaaaaaaaaaaa A	168.60	+26.01%	212.45
Aaaa Aaaa	640.00	+16.86%	747.90

See full list

Install Our AppScan QR code to install app

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers

Popular Searches

Please try another search

United Pharm (033270)

033270 Income Statement

Trending Stocks